A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway
文献类型：期刊论文
| 作者 | Gao,Xuejie2; Li,Bo1; Ye,Anqi3; Wang,Houcai2; Xie,Yongsheng2; Yu,Dandan2; Xu,Zhijian1 ; Shi,Bingqing2; Zhang,Hui2; Feng,Qilin2
|
| 刊名 | Cancer Cell International
 |
| 出版日期 | 2021-05-30 |
| 卷号 | 21期号:1 |
| 关键词 | Multiple myeloma Anti-tumor activity NF-κB |
| DOI | 10.1186/s12935-021-01973-1 |
| 通讯作者 | Shi,Jumei(shijumei@tongji.edu.cn) ; Zhu,Weiliang(wlzhu@simm.ac.cn) |
| 英文摘要 | AbstractBackgroundMultiple myeloma (MM) is a highly aggressive and incurable clonal plasma cell disease with a high rate of recurrence. Thus, the development of new therapies is urgently needed. DCZ0805, a novel compound synthesized from osalmide and pterostilbene, has few observed side effects. In the current study, we intend to investigate the therapeutic effects of DCZ0805 in MM cells and elucidate the molecular mechanism underlying its anti-myeloma activity.MethodsWe used the Cell Counting Kit-8 assay, immunofluorescence staining, cell cycle assessment, apoptosis assay, western blot analysis, dual-luciferase reporter assay and a tumor xenograft mouse model to investigate the effect of DCZ0805 treatment both in vivo and in vitro.ResultsThe results showed that DCZ0805 treatment arrested the cell at the G0/G1 phase and suppressed MM cells survival by inducing apoptosis via extrinsic and intrinsic pathways. DCZ0805 suppressed the NF-κB signaling pathway activation, which may have contributed to the inhibition of cell proliferation. DCZ0805 treatment remarkably reduced the tumor burden in the immunocompromised xenograft mouse model, with no obvious toxicity observed.ConclusionThe findings of this study indicate that DCZ0805 can serve as a novel therapeutic agent for the treatment of MM. |
| 语种 | 英语 |
| WOS记录号 | BMC:10.1186/S12935-021-01973-1 |
| 出版者 | BioMed Central |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/296472]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Shi,Jumei; Zhu,Weiliang |
| 作者单位 | 1.Shanghai Institute of Materia Medica, Chinese Academy of Sciences; CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center 2.Tongji University School of Medicine; Department of Hematology, Shanghai Tenth People’s Hospital 3.Shanghai JiaoTong University School of Medicine; Shanghai Children’s Medical Center |
| 推荐引用方式 GB/T 7714 | Gao,Xuejie,Li,Bo,Ye,Anqi,et al. A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway[J]. Cancer Cell International,2021,21(1). |
| APA | Gao,Xuejie.,Li,Bo.,Ye,Anqi.,Wang,Houcai.,Xie,Yongsheng.,...&Zhu,Weiliang.(2021).A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway.Cancer Cell International,21(1). |
| MLA | Gao,Xuejie,et al."A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway".Cancer Cell International 21.1(2021). |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。